Pfizer Pipeline. November 8, 2012

Transcription

1 Pfizer Pipeline November 8, 2012

2 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of November 8, Visit Pfizer.com/pipeline, Pfizer s online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world. 2

3 Table of Contents Pfizer Pipeline Snapshot 4 Cardiovascular & Metabolic Diseases 5 Inflammation & Immunology 6 Neuroscience & Pain 7 Oncology 8 Vaccines 9 Other Areas of Focus 10 Projects Discontinued Since Last Update 11 3

4 Pfizer Pipeline Snapshot Discovery Projects 3 programs advanced or are new Pfizer Pipeline Snapshot as of November 8, In Reg Total 78 Pipeline represents progress of R&D programs as of November 8, 2012 Included are 59 NMEs, 17 additional indications, plus 2 biosimilars Discovery Projects 8 projects discontinued since last update 8 programs advanced or are new Recent Approvals - Xeljanz (tofacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate (U.S.) - Xalkori for treatment of previously treated ALK- positive advanced non-small cell lung cancer (EU) - Bosulif (bosutinib) for treatment of previously treated chronic myelogenous leukemia (U.S.) - Inlyta (axitinib) for treatment of advanced renal cell carcinoma after failure of prior systemic treatment (EU) Pfizer Pipeline Snapshot as of August 9, In Reg Total 87 Pipeline represents progress of R&D programs as of August 9, 2012 Included are 65 NMEs, 20 additional indications, plus 2 biosimilars 8 projects discontinued since last update Recent Approval - Lyrica for treatment of central neuropathic pain due to spinal cord injury (U.S.) 4

5 Pfizer Pipeline November 8, 2012 Therapeutic Area Cardiovascular and Metabolic Diseases Compound Name Viviant Eliquis (apixaban) Mechanism of Action ( 3 through regulatory approval) Selective Estrogen Receptor Modulator Factor Xa Inhibitor Osteoporosis Treatment and Prevention (U.S.) Prevention of Stroke and Systemic Embolism in patients with Nonvalvular Atrial Fibrillation (U.S./EU) Registration Registration apixaban Factor Xa Inhibitor Venous Thromboembolism Prevention (U.S.) 3 Eliquis (apixaban) Factor Xa Inhibitor Venous Thromboembolism Treatment 3 PF Diabetes Mellitus-Type 2 2 RN316 (PF ) Hypercholesterolemia (Biologic) 2 PF Diabetes Mellitus-Type 2 2 PF Diabetic Nephropathy 2 CVX 096 (PF ) Diabetes Mellitus-Type 2 (Biologic) 1 PF Diabetes Mellitus-Type 2 (Biologic) 1 PF Diabetes Mellitus-Type 2 1 PF Hypercholesterolemia (Biologic) 1 PF Acute Coronary Syndrome 1 5

6 Pfizer Pipeline November 8, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) tofacitinib (CP ) JAK Inhibitor Rheumatoid Arthritis (EU) Registration tofacitinib (CP ) JAK Inhibitor Psoriasis (Oral) 3 tofacitinib (CP ) JAK Inhibitor Ulcerative Colitis 3 PF Rheumatoid Arthritis 2 PF Ulcerative Colitis (Biologic) 2 Inflammation and Immunology anrukinzumab (IMA-638) Ulcerative Colitis (Biologic) 2 PF Crohn s Disease (Biologic) 2 PF tofacitinib (CP ) Crohn s Disease, Lupus, *Rheumatoid Arthritis (Biologic) Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn s Disease 2 2 PF (EXC 001) Dermal Scarring 2 PD Lupus (Biologic) 1 PF Rheumatoid Arthritis (Biosimilar) 1 Biosimilar * Note: Additional indications in 1 6

7 Pfizer Pipeline November 8, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) tafamidis meglumine Transthyretin (TTR) Dissociation Inhibitor Transthyretin familial amyloid polyneuropathy (U.S.) Registration Celebrex COX-2 Chronic Pain (U.S.) Registration Remoxy Mu-type opioid receptor (MOR-1) Agonist Moderate to Severe Pain (U.S.) Registration ALO-02 Oxycodonenaltrexone core Mu-type opioid receptor (MOR-1) Agonist Moderate to Severe Pain 3 Lyrica Alpha-2 Delta Ligand Peripheral Neuropathic Pain 3 Lyrica Alpha-2 Delta Ligand CR (once a day dosing) 3 Neuroscience & Pain tanezumab Nerve Growth Factor Inhibitor OA Signs and Symptoms (Biologic) 3 PF Schizophrenia 2 PF Stroke Recovery 2 tanezumab Chronic Pain (Biologic) 2 PF Chronic Pain 1 PF (AAB-003) Alzheimer s Disease (Biologic) 1 PF Schizophrenia, Sensorineural Hearing Loss 1 PF (SAM-760) Alzheimer s Disease 1 PF Schizophrenia 1 PF Acute and Chronic Pain 1 7

8 Pfizer Pipeline November 8, 2012 (cont d) Therapeutic Area Oncology Compound Name bosutinib dacomitinib (PF ) Mechanism of Action ( 3 through regulatory approval) Abl and src-family kinase inhibitor pan-her Inhibitor Treatment of Previously Treated Chronic Myelogenous Leukemia (EU) Previously Treated Advanced Non-Small Cell Lung Cancer Registration 3 Xalkori (crizotinib) c-met-alk Inhibitor ALK-Positive 1st and 2nd Line (supports full approval in the U.S.) Non-Small Cell Lung Cancer, *Cancer 3 Inlyta (axitinib) VEGF Tyrosine Kinase Inhibitor Renal Cell Carcinoma Adjuvant (Asia only) 3 Sutent Multiple Tyrosine Kinase Inhibitor Renal Cell Carcinoma Adjuvant 3 inotuzumab ozogamicin Aggressive Non-Hodgkin s Lymphoma (Biologic) 3 inotuzumab ozogamicin Acute Lymphoblastic Leukemia (Biologic) 3 Inlyta (axitinib) Liver Cancer 2 dacomitinib (PF ) Cancer 2 PD st Line Advanced Breast Cancer 2 CVX 060 (PF ) Renal Cell Carcinoma, *Cancer (Biologic) 2 PF Endometrial Cancer, *Cancer 2 PF Cancer 1 PF Cancer (Biologic) 1 PD Cancer (in combination with PF ) 1 * Note: Additional indications in 1 8

9 Pfizer Pipeline November 8, 2012 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) PF Cancer (Biologic) 1 Oncology (cont d) Vaccines PF Cancer (Biologic) 1 PF Metastatic Breast Cancer (Biosimilar) 1 PF Acute Myelocytic Leukemia 1 ACC-001 (PF ) Alzheimer s Disease 2 MnB rlp2086 (PF ) 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF ) Adolescent and Young Adult Meningitis B 3 Staph Aureus 2 PF Smoking Cessation 1 PF Clostridium Difficile Colitis 1 Biosimilar Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com 9

10 Pfizer Pipeline November 8, 2012 (cont d) Therapeutic Area Other Areas of Focus Compound Name Mechanism of Action ( 3 through regulatory approval) bazedoxifeneconjugated estrogens Tissue Selective Estrogen Complex Menopausal Vasomotor Symptoms (EU) Registration Zithromax/chloroquine 5-OS Ribosome Inhibitor Malaria 3 bazedoxifeneconjugated estrogens Tissue Selective Estrogen Complex Menopausal Vasomotor Symptoms (U.S.) 3 bosutinib Autosomal Dominant Polycystic Kidney Disease 2 PF (filibuvir) Hepatitis C Virus 2 tofacitinib (CP ) Transplant Rejection 2 PH Chronic Obstructive Pulmonary Disease 2 PF (GMI-1070) Vaso-occlusive crisis associated with Sickle Cell Disease 2 PNU Tuberculosis 2 RN6G (PF ) Age-Related Macular Degeneration (Biologic) 2 PF Chronic Obstructive Pulmonary Disease 1 PF Hemophilia (Biologic) 1 PF Muscular Dystrophies (Biologic) 1 Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com 10

11 Projects Discontinued from Development since August 9, 2012 Compound Name Mechanism of Action ( 3 through regulatory approval) Taliglucerase alfa Enzyme Replacement Therapy Type 1 Gaucher Disease (Biologic) (EU) Registration Xiapex (EU) Inlyta (axitinib) Clostridial Collagenase for Injection VEGF Tyrosine Kinase Inhibitor Peyronie s Disease (Biologic) (EU) In November 2012, we and our alliance partner, Auxilium Pharmaceuticals, Inc. (Auxilium), announced that we are amending our collaboration agreement for the development, commercialization and supply of Xiapex in the EU and certain other European and Eurasian countries (the Collaboration Agreement). As a result of this amendment, the Collaboration Agreement will terminate no later than April 24, Prior to the mutual termination date, the parties will continue to perform all of their obligations as described in the Collaboration Agreement. After the termination date, rights to commercialize Xiapex in those markets and further development of the indication for Peyronie s disease will revert to Auxilium Advanced Renal Cell Carcinoma in treatmentnaïve patients 3 3 Eraxis/Vfend Beta-D Glucan Synthase Inhibitor, Cyp P450 Mediated Alpha-lanosterol Demethylation Aspergillosis 3 Eladur Chronic Pain 2 PF Endometrial Cancer, *Cancer 2 OAP-189 (PF ) Diabetes Mellitus-Type 2, Obesity (Biologic) 1 PF Diabetic Nephropathy 1 * Note: Additional indications in 1 11